Caris Life Sciences (NASDAQ:CAI) Reaches New 12-Month Low – Here’s Why

Caris Life Sciences, Inc. (NASDAQ:CAI) shares reached a new 52-week low during trading on Monday . The stock traded as low as $22.80 and last traded at $23.56, with a volume of 169898 shares trading hands. The stock had previously closed at $23.16.

Analyst Upgrades and Downgrades

Several research firms have commented on CAI. Weiss Ratings restated a “sell (d)” rating on shares of Caris Life Sciences in a research note on Monday, December 29th. Evercore ISI set a $38.00 target price on shares of Caris Life Sciences in a report on Monday, January 5th. Wall Street Zen raised shares of Caris Life Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, January 17th. Finally, Canaccord Genuity Group upped their target price on Caris Life Sciences from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Monday, December 22nd. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $34.00.

Caris Life Sciences Trading Up 0.9%

The stock has a market capitalization of $6.59 billion and a PE ratio of -50.80. The company has a debt-to-equity ratio of 0.79, a quick ratio of 9.36 and a current ratio of 9.93.

Insider Buying and Selling

In other Caris Life Sciences news, insider Luke Thomas Power sold 62,250 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the transaction, the insider owned 99,571 shares in the company, valued at $2,646,597.18. This trade represents a 38.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Caris Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of CAI. Diversified Trust Co. bought a new stake in Caris Life Sciences in the 4th quarter valued at about $540,000. Olistico Wealth LLC acquired a new stake in shares of Caris Life Sciences in the fourth quarter valued at approximately $31,000. Zevenbergen Capital Investments LLC acquired a new position in Caris Life Sciences in the 4th quarter valued at $14,655,000. Hamilton Lane Advisors LLC bought a new stake in shares of Caris Life Sciences during the 4th quarter valued at $1,584,000. Finally, Sumitomo Mitsui Trust Group Inc. increased its position in shares of Caris Life Sciences by 26.5% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 75,330 shares of the company’s stock worth $2,032,000 after purchasing an additional 15,778 shares during the period.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.